發(fā)布時(shí)間：2022-08-23 22:35

　　新型冠狀病毒肺炎（COVID-19）是一種由嚴(yán)重急性呼吸綜合征冠狀病毒2（SARS-CoV-2）引起的新型傳染病。SARS-CoV-2具有極強(qiáng)的傳染性,因此在引發(fā)流行病后又使其迅速升級(jí)為全球大流行,至今仍在部分國(guó)家迅速傳播。在COVID-19的感染者中,存在腫瘤等慢性病或伴有相關(guān)合并癥的患者預(yù)后往往較差。同時(shí),由于惡性血液腫瘤患者長(zhǎng)期處于免疫抑制狀態(tài),往往感染風(fēng)險(xiǎn)更高且預(yù)后更差,所以十分值得我們關(guān)注。這篇綜述歸納并分析了惡性血液腫瘤患者合并COVID-19后的臨床表現(xiàn)。此外,歸納了疫情期間惡性腫瘤的管理策略和感染后的綜合干預(yù)措施,旨在為臨床提供指導(dǎo)。 

【文章頁(yè)數(shù)】：19 頁(yè)

【文章目錄】：
1 Introduction
2 Regional reports of SARS-Co V-2 infections in patients with HMs
3 Specific clinical manifestations,radiologic patterns,and laboratory findings in patients with COVID-19 and HMs
    3.1 Clinical manifestations
    3.2 Radiologic findings
    3.3 Laboratory tests
4 Clinical diagnostic criteria and differential diagnoses of patients with COVID-19 and HMs
5 General management strategies for patients with HMs during the COVID-19 pandemic
    5.1 Considerations for hospital admission procedures
    5.2 Considerations for hematological therapeutic regimens
        5.2.1 Chemotherapy
        5.2.2 Immunotherapy
        5.2.3 Hematopoietic stem cell transplantation
        5.2.4 Recommendations for regimen adjustments
            5.2.4. 1 Acute leukemia
            5.2.4. 2 Chronic leukemia
            5.2.4. 3 Lymphoma
            5.2.4. 4 Multiple myeloma
    5.3 Considerations for follow-up plans
6 Comprehensive intervention strategies for patients with COVID-19 and preexisting HMs
7 Conclusions
Contributors
Compliance with ethics guidelines


【參考文獻(xiàn)】：
期刊論文
[1]2019冠狀病毒病流行期間兒童血液腫瘤病房規(guī)范化管理建議[J]. 邱奕寧,李力,吳小艷,金潤(rùn)銘.  中國(guó)當(dāng)代兒科雜志. 2020(03)



本文編號(hào)：3678608